Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas

Journal of Neuro-Oncology

Volumn 120, Issue 2, 2014, Pages 283-291

  Suzuki, Aya ^a   Nobusawa, Sumihito ^a   Natsume, Atsushi ^b   Suzuki, Hiromichi ^b   Kim, Young Ho ^c,d   Yokoo, Hideaki ^a   Nagaishi, Masaya ^a,e   Ikota, Hayato ^a   Nakazawa, Takuro ^a   Wakabayashi, Toshihiko ^b   Ohgaki, Hiroko ^c   Nakazato, Yoichi ^a,f  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d National Cancer Center   (South Korea)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f Hidaka Hospital   (Japan)

Author keywords

Diffuse astrocytoma; Low grade diffuse glioma; Olig2; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P53; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NERVE PROTEIN; OLIG2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; GENOTYPE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LOW GRADE DIFFUSE GLIOMA; MALE; MOLECULAR DIAGNOSIS; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; BRAIN TUMOR; CHROMOSOME 1; CLASSIFICATION; FOLLOW UP; GENETICS; HETEROZYGOSITY LOSS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NERVE TISSUE PROTEINS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84910115550     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1568-1     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
2. Zhou Q, Choi G, Anderson DJ (2001) The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 31:791–807
3. Copray S, Balasubramaniyan V, Levenga J, de Bruijn J, Liem R, Boddeke E (2006) Olig2 overexpression induces the in vitro differentiation of neural stem cells into mature oligodendrocytes. Stem Cells 24:1001–1010
4. Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K, Nabeshima Y (2002) The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr Biol 12:1157–1163
5. Lu QR, Park JK, Noll E et al (2001) Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 98:10851–10856
6. Yokoo H, Nobusawa S, Takebayashi H et al (2004) Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol 164:1717–1725
7. Aguirre-Cruz L, Mokhtari K, Hoang-Xuan K et al (2004) Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol 67:265–271
8. Ligon KL, Alberta JA, Kho AT et al (2004) The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 63:499–509
9. Mokhtari K, Paris S, Aguirre-Cruz L et al (2005) Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 31:62–69
10. Watanabe T, Nakamura M, Kros JM et al (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267–275
11. Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708–2714
12. Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425
13. Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455
14. Yip S, Butterfield YS, Morozova O et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7–16
15. Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231
16. Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625
17. Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203
18. Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722
19. Sahm F, Koelsche C, Meyer J et al (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123:853–860
20. Tanaka G, Nakazato Y (2004) Automatic quantification of the MIB-1 immunoreactivity in brain tumors. In: Watanabe K et al (eds) Developments in neuroscience. proceedings of the 3rd international Mt. Bandai symposium for neuroscience and the 4th Pan-Pacific neurosurgery congress. Elsevier B.V., Amsterdam, pp 15–19
21. Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69
22. Mehta S, Huillard E, Kesari S, Maire CL et al (2011) The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 19:359–371
23. Sun Y, Meijer DH, Alberta JA et al (2011) Phosphorylation state of Olig2 regulates proliferation of neural progenitors. Neuron 69:906–917
24. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254
25. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474
26. Zhang J, Wu G, Miller CP et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612